Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.
Press Enter β΅ to start review
Explore by Goal
"Study hard what interests you the most in the most undisciplined, irreverent and original manner possible."
- Richard Feynman
Quick Explanation
Copied
Paper: Antiprotozoal activities of symmetrical bishydroxamic acids
Key finding: converting symmetrical bis-ester / bis-carboxylic-acid scaffolds into bishydroxamic acids (and especially Na salts) yields in vitro activity against Plasmodium falciparum (IC50 down to ~0.013 mM for W2) and weaker activity against Leishmania donovani (higher mM IC50). Evidence is entirely in vitro; the proposed mechanism (metal/iron chelation) is hypothesized, not directly tested.
Scaffold origin: methyl 4-hydroxybenzoate is alkylated with different dihalo-alkanes, a dihalogenated alkene (trans-1,4-dichloro-2-butene), or a bis-bromo-ether to install a spacer between two aromatic rings; then hydroxylamine converts the esters to bishydroxamic acids.
Analog logic: the corresponding bisesters and biscarboxylic acids are tested to assess whether the hydroxamic acid functionality is required for activity.
Salt forms: Na salts are evaluated for improved aqueous solubility and potency (notably 11 and 12).
2) Raw potency visualization (IC50; from Table 1 text)
Note on evidence boundaries:
All numeric potency values below are transcribed from the paperβs Table 1 and narrative IC50 ranges. The paper also reports IC90 for some compounds; those are not fully plotted here because the provided excerpt lists many IC90s with formatting ambiguities in the text dump.
3) Key SAR signal (what the inactive analogs imply)
The paper states that bisesters and biscarboxylic acids show no inhibitory activities, whereas hydroxamic acids 1β3 show significant inhibition with sub-millimolar to low-millimolar IC50s against P. falciparum D6/W2.
This provides a clean functional-group-to-activity association: bishydroxamic acid functionality is essential under the assay conditions described.
4) Comparison across organism targets (known vs uncertain)
Known from the paper: sodium salt 12 is notably stronger versus W2 than versus D6 (IC50 ~0.013 mM for W2; ~0.26 mM for D6), indicating target/strain-dependent effects under these in vitro conditions.
Leishmania difference: for L. donovani, the same best candidates (3 and 12) are much less potent (mM-range IC50), suggesting either different uptake/target engagement or that the proposed mechanism may not map 1:1 to Leishmania.
Uncertainty: the paperβs mechanism proposal (metal/iron chelation in hemoglobin) is not directly demonstrated with metal-binding assays, hemoglobin interaction assays, or rescue experiments in the provided text.
Parasite assays (Plasmodium): incubation ~66 h, starting parasitemia 0.2% with 1% hematocrit; RPMI-1640 lacking folate and pABA with 10% heat-inactivated human plasma; dose series 10^48-fold range by serial dilution into 96-well plates; readout: addition of [3H]-hypoxanthine after 42 h and incubate 24 h; harvest by filter mats and scintillation counting; IC50 from nonlinear logistic dose-response.
Parasite assays (Leishmania): axenic amastigote assay over 3 days using a tetrazolium dye-based CellTiter assay; pentamidine as control.
Limitations affecting reproducibility: the excerpt does not provide the exact number of biological replicates per concentration, nor raw concentration-response curves; it reports IC50/IC90 values and uses nonlinear logistic analysis.
Clean negative controls inside the scaffold family: bisesters and biscarboxylic acids are reported inactive while hydroxamic acids are active, supporting the central chemical hypothesis that hydroxamic functionality matters.
Assay description includes key parameters: DMSO solubilization, serial dilution scheme, use of [3H]-hypoxanthine incorporation for Plasmodium, and dose-response logistic fitting are specified.
Red flags / blind spots
No direct mechanistic validation: the mechanism is framed as plausible presumption (chelation with metallic iron in hemoglobin; possible protease pathway links), but within the provided text there is no direct experimental demonstration.
Potency level vs translational relevance: best Plasmodium IC50 values are in the ~0.013β0.26 mM range, while Leishmania IC50 values are much higher (mM tens). That may reflect either true target biology mismatch or assay/solubility constraints. The paper notes solubility differences for compound 3 vs salt 12, which can confound potency comparisons.
No host-cell toxicity data in the provided text: the excerpt focuses on parasite inhibition; it does not provide cytotoxicity/selectivity indexes in the same section. Without these, attributing anti-parasite effects to specific antiparasitic action vs general toxicity is uncertain.
What would disprove the paperβs proposed explanation?
If bishydroxamic acids did not chelate iron under relevant conditions (or did not alter hemoglobin/iron handling) then the βiron chelation in hemoglobinβ explanation would be weakened.
If increased iron availability, iron chelation rescue, or inhibition of the alternative speculated targets (e.g., phosphoribosyltransferase or metalloenzymes) did not change the potency pattern, then target specificity would remain unclear.
7) Potency summary table (transcribed from Table 1 where available)
Compound
P. falciparum D6 IC50 (mM)
P. falciparum W2 IC50 (mM)
L. donovani IC50 (mM)
Bishydroxamic acid 1
2.2
3.2
β
Bishydroxamic acid 2
0.69
1.05
β
Bishydroxamic acid 3
0.24
0.35
18.5 Β± 6.0
Bishydroxamic acid sodium salt 11
0.47
1.09
β
Bishydroxamic acid sodium salt 12
0.26
0.013
37.4 Β± 14.0
Chloroquine
0.013
0.45
β
Mefloquine
0.45
0.008
β
Values are transcribed from the excerpted Table 1 narrative text and accompanying IC50 descriptions. Where the excerpt does not explicitly provide the L. donovani IC50 for compounds 1/2/11 or other controls, entries are left as βββ.
Buttons for deeper BGPT dives
Author reviews (BGPT)
Feedback:
Updated: April 09, 2026
BGPT Paper Review
Study Novelty
50%
The paperβs main novelty is a straightforward medicinal-chemistry expansion: symmetrical bishydroxamic acid scaffolds with varied spacer chemistry and evaluation of both acids and Na salts. However, the hydroxamate-as-metal-chelator concept and broad antiparasitic rationale are presented as established background rather than a new paradigm.
Scientific Quality
50%
Scientific quality is moderate-to-limited: methods for parasite assays are described with key parameters, and structure-activity logic (inactive bisesters/biscarboxylic acids vs active hydroxamic acids) is strong. But the excerpt does not show direct mechanistic validation, host-cell toxicity/selectivity data, replicate counts, or raw concentration-response curves; mechanism is therefore largely inferential.
Study Generality
40%
The results are confined to a small set of symmetrical bishydroxamic acids (and two Na salts) and to specific parasite models/strains (P. falciparum D6/W2 clones; L. donovani axenic amastigotes). The conclusions may not generalize across other spacers, parasite isolates, or in vivo contexts.
Study Usefulness
60%
Useful as a chemistry-to-bioactivity starting point: it identifies bishydroxamic acid functionality as essential for activity in these assays and highlights that Na salt formation can substantially change potency (notably against W2). But practical drug-development value is limited by the lack of in vivo and selectivity/toxicity data in the excerpt.
Study Reproducibility
60%
The Plasmodium assay parameters and readout are described, and the Leishmania assay approach is specified, including key incubation and detection approach. However, the excerpt does not specify biological replicate numbers or provide raw response curves; no data repository is indicated.
Explanatory Depth
60%
Mechanistic reasoning is plausible but not experimentally closed: it connects hydroxamates to metal chelation and speculated pathways, but the excerpt does not include mechanistic experiments that establish the target(s).
Extract IC50s from Table 1 text into a structured table, then generate log-scale comparative plots and a D6-vs-W2 crossplot using the provided potency values.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
βBishydroxamic acids are just general iron chelators that will work similarly across protozoa.β Likely wrong here because L. donovani inhibition is far weaker than Plasmodium inhibition despite the same hydroxamic chemistry.
βInactive analogs mean the whole spacer is irrelevant.β This is too strong: while bisesters/biscarboxylic acids are inactive, the activity differs among hydroxamic acids (1 vs 2 vs 3), so the spacer still modulates effective target engagement (likely via conformation/solubility/chelation geometry).
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Keep Exploring
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Explore by Goal
Ask a Follow-Up
Key Insight
